Ward Medication Management Ward Medication Management Ward Medication Management Ward Medication Management
  • Home
  • About Us
  • Services
  • Partners
  • Careers
  • News
  • Knowledge Hub
  • Contact Us
  • Sign In
Ward Medication Management Ward Medication Management
  • Home
  • About Us
  • Services
  • Partners
  • Careers
  • News
  • Knowledge Hub
  • Contact Us
  • Sign In
Oct 10

Ward Clinical Pearl: 10 October 2016 – Hypomagnesaemia

  • October 10, 2016
  • Joanna Foy
  • No Comments
  • Clinical Pearls

Each week we will aim to bring out a concise email that provides 4-5 key pieces of information addressing a specific issue in clinical therapeutics.

 

This week: Hypomagnesaemia
Clinical consequences of hypomagnesaemia include nausea, fatigue, delirium, muscle cramps, cardiacarrhythmias and seizures; however some patients do not report any symptoms. Various drugs can result in a reduced the serum magnesium concentration (hypomagnesaemia)

 

  • Low magnesium has been associated with a number of medicines including aminoglycosides such as gentamicin, cyclosporin & tacrolimus, and various diuretics including thiazide agents and loop diuretics (frusemide). Over-consumption of alcohol can also be implicated as a cause of low serum magnesium.
  • There is now evidence to link hypomagnesaemia with the administration of Proton Pump Inhibitors (PPIs) such as pantoprazole, esomeprazole, omeprazole, lansoprazole and rabeprazole.
  • It is postulated that magnesium regulation is controlled by intestinal absorption and renal excretion. Case reports have demonstrated that PPIs do not affect renal excretion but interfere with transport mechanisms in the small intestine. Active transport mechanisms involving receptors in the gut increase when GI magnesium levels are low, increasing magnesium absorption. It is thought that the change in gastrointestinal pH caused by PPIs affects the active transport channels,resulting in hypomagnesaemia once body stores are eventually reduced.
  • Serum magnesium concentrations should be monitored for patients treated with long-term PPI therapy. Long-term oral magnesium supplementation may be needed if the proton pump inhibitor cannot be discontinued.

Please consider these issues when preparing or interpreting RMMR reports or education sessions. Contributions of content or suggested topics are welcome and should be sent directly to chris@wardmm.com.au.

  • Facebook
  • Twitter
  • Tumblr
  • Pinterest
  • Google+
  • LinkedIn
  • E-Mail

About The Author

Leave a reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Ward Clinical Pearl: 17 April 2018 – Methotrexate SC Injection
  • Ward Clinical Pearl: 10 April 2018 – Direct/Newer Anticoagulants Part 2
  • Ward Clinical Pearl: 3 April 2018 – Direct/Newer Anticoagulants Part 1
  • Ward MM Newsletter March 2018
  • Ward Clinical Pearl: 27 March 2018 – Updating Medicine Ingredients Names Part 2

Archives

  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015

Categories

  • Clinical Pearls
  • Company News
  • Newsletters

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

© Ward Medication Management 2017 All Rights Reserved | Privacy Policy | Ethics Statement